Current pharmacotherapy of bradykinin-mediated angioedema. - Wikidata - awgldk - TriplyDB

Current pharmacotherapy of bradykinin-mediated angioedema.

Current pharmacotherapy of bradykinin-mediated angioedema.

http://www.wikidata.org/entity/Q38088259

about

Examination of genetic variants involved in generation and biodisposition of kinins in patients with angioedema Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema.The effect of long-term danazol treatment on haematological parameters in hereditary angioedema Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency.Treatment of hereditary angioedema: a review (CME).Hereditary angioedema: imaging manifestations and clinical management.The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.Icatibant as acute treatment for hereditary angioedema in adults.Hydrogen Sulfide Releasing 2-Mercaptoacrylic Acid-Based Derivative Possesses Cytoprotective Activity in a Small Intestine of Rats with Medication-Induced Enteropathy.First report of icatibant treatment in a pregnant patient with hereditary angioedema.

P2860

Q23915359-1FD6CC16-2AE5-4613-B83C-9917FDD81781 Q27009012-CD34A9E2-EA29-4B9E-B00A-62782C68C8AD Q29248157-10D15B45-2399-4B89-953E-4041238658D4 Q34721347-62AF068B-9EB7-49DE-A218-B2763CE72644 Q36616407-76DEF4D5-47DA-4D5A-9A2B-E8C5F782CB3D Q37576393-6BCAE5D1-2BB8-473B-B3D6-E3E63CE7CFC2 Q38204788-85508E6D-CECF-4F14-A538-9E3BE2C55BF6 Q38216306-1967D811-811E-490B-BED9-23F859AF49E4 Q38597515-65C094EE-420C-4FCF-B217-D1AE5DB7587C Q38819740-2E554EC7-7B6D-4BEC-864D-E05091D209C8 Q50075649-DC3A45AB-E8C0-4139-9879-2371393BA94A Q50907177-8531C5C1-5D35-47D6-A2F3-0D5F6D90B1FB

P2860

Current pharmacotherapy of bradykinin-mediated angioedema.

http://www.wikidata.org/entity/Q38088259

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current pharmacotherapy of bradykinin-mediated angioedema.

@en

type

label

Current pharmacotherapy of bradykinin-mediated angioedema.

@en

prefLabel

Current pharmacotherapy of bradykinin-mediated angioedema.

@en

P1433

Q38088259-D4AF9BCF-11CD-4DB0-8E31-D2E38B31D4D5

P1476

Q38088259-A73DC530-8130-4C9C-993B-73EEE37B9991

P2093

Q38088259-55B4A141-DE70-4A34-A4DA-32E9BB3AF433

P2860

Q38088259-025059DA-30D3-47E3-BECD-D571832E72BC

Q38088259-0287FA39-9050-4AE0-9234-66FAB73AB2CF

Q38088259-03798709-2D8A-47B9-81F0-C9735D6EE6AD

Q38088259-044E0361-7B08-40C3-ABFA-FEAE4465E78F

Q38088259-0736087B-865F-4E4F-96D1-6511826E8509

Q38088259-0CA79176-E5E0-412D-A2B1-8147581C4F73

Q38088259-0D95D649-50CA-4EDC-A432-D1E18CB1EB2B

Q38088259-107A7A08-777A-44AF-B482-2AC11CC61C3B

Q38088259-11120C26-CB17-4DCA-BA82-A314E94AAFB9

Q38088259-1130BD67-884B-40F9-8593-6ED73A3C18CA

P304

Q38088259-C6A0A83D-C468-4F75-AF26-58B864FB70E2

P31

Q38088259-68A8A7E1-1F47-40C5-BB4D-F76E27B140B1

P356

Q38088259-DAC47ACA-5537-4C77-A382-21609A78BEEF

P407

Q38088259-AA203091-AF23-4F7F-8DEF-443C9BBB2126

P433

Q38088259-7639BAC7-7E18-4FE0-A4F0-B6967FE00972

P478

Q38088259-B9EF8A99-EF5C-4CE8-821D-1A7CBB73F5E3

P50

Q38088259-ECD03489-B837-4913-A78E-AC856AD77C71

P577

Q38088259-90BF673A-29BB-416C-AF73-28AE3FB72E6E

P698

Q38088259-515A263B-38D1-40BF-A43F-0870BEB61D44

P921

Q38088259-24578700-8C2A-4CD4-BE70-6F253C595811

P356

14656566.2013.778826

P1433

Expert Opinion on Pharmacotherapy

P1476

Current pharmacotherapy of bradykinin-mediated angioedema

@en

P2093

Henriette Farkas

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor

Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III

Angioedema without urticaria: a large clinical survey

Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema

Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate

Danazol may cause female pseudohermaphroditism

Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies

Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency.

Hereditary angioedema with normal C1-inhibitor activity in women.

P304

571-586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.778826

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Henriette Farkas

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23480060

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy